Kiora Historical Balance Sheet

KPRX Stock

USD 3.00 0.01 0.33%

Trend analysis of Kiora Pharmaceuticals balance sheet accounts such as Total Current Liabilities of 3.3 M provides information on Kiora Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Kiora Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Kiora Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Kiora Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Kiora Pharmaceuticals is a good buy for the upcoming year.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.

About Kiora Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Kiora Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Kiora Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Kiora Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Kiora currently owns. An asset can also be divided into two categories, current and non-current.

Kiora Pharmaceuticals Balance Sheet Chart

At this time, Kiora Pharmaceuticals' Other Current Assets are fairly stable compared to the past year. Total Liabilities is likely to rise to about 12.2 M in 2025, whereas Short and Long Term Debt Total is likely to drop slightly above 54.3 K in 2025.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Kiora Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Kiora Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Kiora Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Kiora Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Kiora Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Kiora Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.At this time, Kiora Pharmaceuticals' Other Current Assets are fairly stable compared to the past year. Total Liabilities is likely to rise to about 12.2 M in 2025, whereas Short and Long Term Debt Total is likely to drop slightly above 54.3 K in 2025.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	105.8K	106.9K	57.2K	54.3K
Total Assets	18.7M	13.7M	36.5M	38.3M

Short Long Term Debt Total Total Assets

Kiora Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Intangible Assets	Other Liab	Net Tangible Assets
Total Assets		-0.38	0.94	0.21	0.85	0.43	-0.39	-0.87	0.22	0.39	0.58	-0.46	0.92	0.81	0.88	-0.66	0.93	0.76	-0.6	0.93	-0.39	0.67	0.37	0.44	0.82	0.8
Short Long Term Debt Total	-0.38		-0.3	0.02	-0.54	-0.26	0.7	0.35	-0.05	-0.52	-0.31	0.76	-0.31	-0.25	-0.18	0.52	-0.25	-0.44	0.56	-0.32	1.0	-0.32	-0.29	-0.14	-0.24	-0.32
Other Current Liab	0.94	-0.3		0.24	0.68	0.2	-0.21	-0.71	0.24	0.2	0.34	-0.37	0.96	0.81	0.97	-0.47	0.96	0.56	-0.38	0.97	-0.31	0.58	0.33	0.28	0.7	0.63
Total Current Liabilities	0.21	0.02	0.24		0.22	-0.04	-0.31	-0.08	0.55	0.38	0.09	0.18	0.23	-0.03	0.08	-0.38	0.18	0.16	-0.16	0.22	0.02	0.34	0.87	-0.17	-0.14	-0.17
Total Stockholder Equity	0.85	-0.54	0.68	0.22		0.51	-0.64	-0.86	0.31	0.62	0.73	-0.62	0.66	0.63	0.55	-0.94	0.66	0.9	-0.93	0.69	-0.55	0.64	0.41	0.42	0.68	0.78
Property Plant And Equipment Net	0.43	-0.26	0.2	-0.04	0.51		-0.51	-0.64	0.12	0.53	0.59	-0.33	0.22	0.38	0.15	-0.44	0.29	0.64	-0.47	0.25	-0.24	0.17	0.14	0.66	0.65	0.63
Net Debt	-0.39	0.7	-0.21	-0.31	-0.64	-0.51		0.34	-0.15	-0.97	-0.28	0.53	-0.35	-0.17	-0.06	0.71	-0.22	-0.5	0.7	-0.35	0.68	-0.54	-0.48	-0.05	-0.14	-0.33
Retained Earnings	-0.87	0.35	-0.71	-0.08	-0.86	-0.64	0.34		-0.2	-0.32	-0.81	0.48	-0.63	-0.79	-0.65	0.72	-0.69	-0.92	0.71	-0.67	0.35	-0.48	-0.31	-0.66	-0.91	-0.93
Accounts Payable	0.22	-0.05	0.24	0.55	0.31	0.12	-0.15	-0.2		0.16	0.33	0.05	0.1	0.11	0.08	-0.42	0.1	0.25	-0.31	0.11	-0.04	-0.01	0.42	0.25	0.1	-0.04
Cash	0.39	-0.52	0.2	0.38	0.62	0.53	-0.97	-0.32	0.16		0.24	-0.4	0.36	0.16	0.06	-0.69	0.23	0.46	-0.66	0.36	-0.5	0.57	0.49	0.02	0.12	0.31
Non Current Assets Total	0.58	-0.31	0.34	0.09	0.73	0.59	-0.28	-0.81	0.33	0.24		-0.39	0.2	0.35	0.23	-0.7	0.33	0.86	-0.7	0.24	-0.31	0.28	0.31	0.75	0.73	0.72
Non Currrent Assets Other	-0.46	0.76	-0.37	0.18	-0.62	-0.33	0.53	0.48	0.05	-0.4	-0.39		-0.36	-0.39	-0.28	0.55	-0.33	-0.54	0.63	-0.37	0.77	-0.34	-0.09	-0.27	-0.41	-0.48
Cash And Short Term Investments	0.92	-0.31	0.96	0.23	0.66	0.22	-0.35	-0.63	0.1	0.36	0.2	-0.36		0.76	0.94	-0.45	0.96	0.49	-0.38	1.0	-0.32	0.68	0.3	0.14	0.61	0.6
Net Receivables	0.81	-0.25	0.81	-0.03	0.63	0.38	-0.17	-0.79	0.11	0.16	0.35	-0.39	0.76		0.83	-0.41	0.73	0.62	-0.41	0.8	-0.25	0.36	0.08	0.52	0.82	0.72
Common Stock Shares Outstanding	0.88	-0.18	0.97	0.08	0.55	0.15	-0.06	-0.65	0.08	0.06	0.23	-0.28	0.94	0.83		-0.29	0.95	0.45	-0.23	0.95	-0.18	0.51	0.14	0.26	0.7	0.62
Non Current Liabilities Total	-0.66	0.52	-0.47	-0.38	-0.94	-0.44	0.71	0.72	-0.42	-0.69	-0.7	0.55	-0.45	-0.41	-0.29		-0.43	-0.84	0.97	-0.47	0.53	-0.58	-0.54	-0.29	-0.46	-0.6
Other Current Assets	0.93	-0.25	0.96	0.18	0.66	0.29	-0.22	-0.69	0.1	0.23	0.33	-0.33	0.96	0.73	0.95	-0.43		0.54	-0.36	0.96	-0.26	0.62	0.29	0.23	0.7	0.66
Other Stockholder Equity	0.76	-0.44	0.56	0.16	0.9	0.64	-0.5	-0.92	0.25	0.46	0.86	-0.54	0.49	0.62	0.45	-0.84	0.54		-0.85	0.53	-0.44	0.48	0.33	0.58	0.78	0.85
Total Liab	-0.6	0.56	-0.38	-0.16	-0.93	-0.47	0.7	0.71	-0.31	-0.66	-0.7	0.63	-0.38	-0.41	-0.23	0.97	-0.36	-0.85		-0.4	0.56	-0.51	-0.34	-0.34	-0.48	-0.64
Total Current Assets	0.93	-0.32	0.97	0.22	0.69	0.25	-0.35	-0.67	0.11	0.36	0.24	-0.37	1.0	0.8	0.95	-0.47	0.96	0.53	-0.4		-0.32	0.67	0.3	0.19	0.65	0.63
Short Term Debt	-0.39	1.0	-0.31	0.02	-0.55	-0.24	0.68	0.35	-0.04	-0.5	-0.31	0.77	-0.32	-0.25	-0.18	0.53	-0.26	-0.44	0.56	-0.32		-0.33	-0.29	-0.13	-0.24	-0.32
Common Stock	0.67	-0.32	0.58	0.34	0.64	0.17	-0.54	-0.48	-0.01	0.57	0.28	-0.34	0.68	0.36	0.51	-0.58	0.62	0.48	-0.51	0.67	-0.33		0.38	-0.11	0.28	0.54
Current Deferred Revenue	0.37	-0.29	0.33	0.87	0.41	0.14	-0.48	-0.31	0.42	0.49	0.31	-0.09	0.3	0.08	0.14	-0.54	0.29	0.33	-0.34	0.3	-0.29	0.38		0.01	0.07	0.05
Intangible Assets	0.44	-0.14	0.28	-0.17	0.42	0.66	-0.05	-0.66	0.25	0.02	0.75	-0.27	0.14	0.52	0.26	-0.29	0.23	0.58	-0.34	0.19	-0.13	-0.11	0.01		0.81	0.57
Other Liab	0.82	-0.24	0.7	-0.14	0.68	0.65	-0.14	-0.91	0.1	0.12	0.73	-0.41	0.61	0.82	0.7	-0.46	0.7	0.78	-0.48	0.65	-0.24	0.28	0.07	0.81		0.87
Net Tangible Assets	0.8	-0.32	0.63	-0.17	0.78	0.63	-0.33	-0.93	-0.04	0.31	0.72	-0.48	0.6	0.72	0.62	-0.6	0.66	0.85	-0.64	0.63	-0.32	0.54	0.05	0.57	0.87

Click cells to compare fundamentals

Kiora Pharmaceuticals Account Relationship Matchups

Kiora Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	15.2M	18.1M	18.7M	13.7M	36.5M	38.3M
Short Long Term Debt Total	362.1K	209.4K	105.8K	106.9K	57.2K	54.3K
Other Current Liab	1.3M	1.2M	2.1M	1.4M	5.6M	5.8M
Total Current Liabilities	1.8M	1.6M	3.3M	1.6M	6.0M	3.3M
Total Stockholder Equity	7.0M	9.2M	11.4M	6.1M	25.8M	27.0M
Property Plant And Equipment Net	30.6K	283.4K	172.2K	115.0K	62.4K	76.1K
Net Debt	(823.6K)	(7.6M)	(5.9M)	(2.3M)	(3.7M)	(3.9M)
Retained Earnings	(108.3M)	(124.7M)	(134.5M)	(147.0M)	(143.4M)	(150.6M)
Accounts Payable	434.8K	160.6K	1.0M	206.3K	415.6K	484.4K
Cash	1.2M	7.9M	6.0M	2.5M	3.8M	4.7M
Non Current Assets Total	13.3M	9.1M	11.0M	9.0M	6.8M	6.2M
Non Currrent Assets Other	102.1K	88.0K	82.3K	45.0K	29.0K	27.5K
Cash And Short Term Investments	1.2M	7.9M	6.0M	2.5M	26.8M	28.1M
Net Receivables	91.0K	529.6K	1.4M	2.0M	2.4M	2.5M
Common Stock Shares Outstanding	114.8K	241.1K	732.3K	538.0K	4.1M	4.3M
Liabilities And Stockholders Equity	15.2M	18.1M	18.7M	13.7M	36.5M	38.3M
Non Current Liabilities Total	6.4M	7.2M	4.0M	6.0M	4.7M	4.5M
Other Current Assets	449.6K	1.2M	343.1K	233.4K	2.9M	3.1M
Other Stockholder Equity	116.8M	135.4M	146.0M	153.2M	169.2M	100.5M
Total Liab	8.2M	8.8M	7.3M	7.6M	10.7M	12.2M
Total Current Assets	1.8M	9.0M	7.7M	4.7M	29.7M	31.2M
Accumulated Other Comprehensive Income	(802.0)	(86.4K)	(182.7K)	(182.8K)	(282.2K)	(268.1K)
Short Term Debt	260.6K	237.7K	211.6K	47.1K	23.4K	22.2K
Common Stock	55.6K	126.6K	18.0K	77.1K	267.7K	281.1K
Intangible Assets	9.7M	8.7M	10.7M	8.8M	6.7M	7.8M
Other Liab	1.5M	2.1M	6.1M	7.1M	8.2M	8.6M
Net Tangible Assets	7.2M	4.9M	3.3M	9.1M	10.4M	10.9M
Other Assets	4.0M	4.0M	0.0	1.0	0.9	0.86
Capital Lease Obligations	83.9K	209.4K	105.8K	106.9K	122.9K	96.0K
Net Invested Capital	7.3M	9.2M	11.4M	6.1M	7.0M	7.5M
Non Current Liabilities Other	5.3M	6.5M	3.3M	5.1M	5.9M	3.8M
Net Working Capital	37.8K	7.4M	4.4M	3.1M	3.6M	2.5M
Property Plant Equipment	43.5K	16.8K	30.6K	283.4K	325.9K	342.2K
Capital Stock	55.6K	126.6K	18.0K	77.1K	69.4K	100.8K
Property Plant And Equipment Gross	123.5K	396.5K	289.5K	121.2K	139.4K	226.7K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Kiora Stock Analysis

When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kiora Historical Balance Sheet

About Kiora Balance Sheet Analysis

Kiora Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Kiora Pharmaceuticals balance sheet Correlations

Kiora Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kiora Pharmaceuticals balance sheet Accounts

Also Currently Popular

Additional Tools for Kiora Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Term Debt	+ 1.0	Short Long Term Debt Total
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock Shares Outstanding	+ 0.97	Other Current Liab
Total Current Assets	+ 0.97	Other Current Liab
Total Liab	+ 0.97	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.96	Other Current Liab

Cash	- 0.97	Net Debt
Non Current Liabilities Total	- 0.94	Total Stockholder Equity
Net Tangible Assets	- 0.93	Retained Earnings
Total Liab	- 0.93	Total Stockholder Equity
Other Stockholder Equity	- 0.92	Retained Earnings
Other Liab	- 0.91	Retained Earnings